Histone Deacetylase Inhibitors as Anticancer Drugs
Open accessThe DOI matches its Crossref record; 181 of the 184 references it cites were found in a registry or an index.
Abstract
Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes. Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT). HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response. Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc. HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy. HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma. Other HDAC inhibitors are in clinical trials for the treatment of hematological and solid malignancies. The results of such studies are promising but further larger studies are needed. Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance. Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclinical and clinical studies, including the combination with other therapeutic modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HDAC inhibitors have been considered for usage in combinatorial therapies for several cancers including melanoma47,65–67.”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“They work as anticancer drugs by inducing cell cycle arrest, differentiation, and cell death, and by reducing angiogenesis and modulating the immune response; however, the mechanisms of their effects can differ depending on the individual HDAC inhibitor and its dose and on the type of cancer [164].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [164]
In the citing paper
“HDAC inhibitors act as antitumoral agents by antagonizing the pro-transcriptional effects of histone deacetylation and silencing the expression of oncogenic factors through chromatin remodeling43.”
From Causal identification of single-cell experimental perturbation effects with CINEMA-OT (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Dasmahapatra, G., Lembersky, D., Kramer, L., Fisher, R. I., Friedberg, J., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 105 · cited 2×
“SAHA carfilzomib in vitro and nude mice xenografts, lymphoma cell SUDHL16, SUDHL4 , SUDHL6, OCI-LY10, OCI-LY3 bortezomib-resistant SUDHL16-10BR, OCI-LY10-40BR and lymphoma cells frompatients Potentiation [152]”
BackgroundRetractedDasmahapatra, G., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 57 · cited 2×
“SNDX-275, SAHA carfilzomib, bortezomib in vitro and nude mice xenografts, lymphoma cell Granta 519, Rec-1, HF-4B, JVM-2, MINO, JVM-13 Potentiation [153]”
BackgroundRetractedBalliu, M., Guandalini, L., Romanelli, M. N., D’Amico, M., & Paoletti, F. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12345 · Cited by 31 · cited 3×
“Moreover, inhibition of HDAC6 activates naïve T cells [119,120].”
BackgroundRetractedThe Wnt Signaling Pathway in Development and Disease
Logan, C. Y., & Nusse, R. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.113126 · Cited by 5,325 · cited 1×
“The Wnt signaling pathway plays an important role in various cancers such as colon, breast, ovarian, prostate and endometrial cancers as well as medulloblastoma and melanoma [103].”
BackgroundMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 1×
“Several tumor associated antigens have been shown to be epigenetically silenced in malignancies impede immune recognition by cytotoxic T cells and contributing to worse prognosis [124,125].”
BackgroundActivation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., et al. (2004) · Science · doi:10.1126/science.1094637 · Cited by 3,239 · cited 14×
“We found that VPA and TSA change CYP enzyme expression in neuroblastoma cells [135].”
BackgroundInfluentialCancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203 · cited 2×
“Therefore, HDACs may be essential for the maintenance of a set of key genes required for survival and growth of cancer cells but not of normal ones [38].”
BackgroundAnticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“HATs catalyze the transfer of an acetyl group from acetyl-CoA to the ε-NH2 group of lysine residues in proteins, while HDACs remove it [12].”
BackgroundRegulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D., Gratton, J.-P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,608 · cited 1×
“eNOS, Akt in vitro endothelial cells, Akt transfected, mutatnteNOS / [110]”
Background
Cited by
Items 201–300 of 1,000
PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia
Gawel, J. M., Shouksmith, A. E., Raouf, Y. S., Nawar, N., Toutah, K., Bukhari, S., Manaswiyoungkul, P., Olaoye, O. O., Israelian, J., Radu, T. B., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112411 · Cited by 41
Mangiatordi, G. F., Intranuovo, F., Delre, P., Abatematteo, F. S., Abate, C., Niso, M., Creanza, T. M., Ancona, N., Stefanachi, A., & Contino, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01357 · Cited by 52
Fu, W., Li, H., Fu, H., Zhao, S., Shi, W., Sun, M., & Li, Y. (2020) · Journal of Immunology Research · doi:10.1155/2020/8820355 · Cited by 55
Zhang, Y., Zhou, L., Safran, H. P., Borsuk, R., Lulla, R. R., Tapinos, N., Seyhan, A. A., & El‐Deiry, W. S. (2021) · Neoplasia · doi:10.1016/j.neo.2021.06.007 · Cited by 51
Inhibitory activities of grape bioactive compounds against enzymes linked with human diseases
Dwibedi, V., Jain, S., Singhal, D., Mittal, A., Rath, S. K., & Saxena, S. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-11801-9 · Cited by 55
Qiu, Q., Chi, F., Zhou, D., Xie, Z., Liu, Y., Wu, H., Yin, Z., Shi, W., & Qian, H. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00036 · Cited by 48
Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53
Mrakovcic, M., Bohner, L. O. L., Hanisch, M. R., & Fröhlich, L. F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123952 · Cited by 52
“Thus, HDACi were found to induce drug-induced effects extending from slight (diarrhea, anorexia and dehydration) to severe (myelosuppression, thrombocytopenia, and cardiotoxicity) phenotypes [50,81,82].”
BackgroundPonnusamy, L., Mahalingaiah, P. K. S., & Singh, K. P. (2019) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.07.011 · Cited by 49
Epigenetic Aberrations in Multiple Myeloma
Caprio, C., Sacco, A., Giustini, V., & Roccaro, A. M. (2020) · Cancers · doi:10.3390/cancers12102996 · Cited by 47
“Indeed, several efforts were made to design and develop HDAC-inhibitors, in terms of both HDAC-specific blockade and pan-HDAC-inhibitors [96].”
BackgroundEffect of Nanomaterials on Gut Microbiota
Ma, Y., Zhang, J., Yu, N., Shi, J., Zhang, Y., Chen, Z., & Jia, G. (2023) · Toxics · doi:10.3390/toxics11040384 · Cited by 51
“Histone deacetylase inhibitors prevent cell growth by halting the cell cycle [16].”
BackgroundEpigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy
Elmallah, M. I. Y., & Micheau, O. (2019) · Cancers · doi:10.3390/cancers11060850 · Cited by 53
“They are categorized into two categories: (1) HDAC isoform-selective inhibitors, which target several types of HDAC, and (2) pan-inhibitors, which act against all type of HDACs [97].”
Role of epigenetics in carcinogenesis: Recent advancements in anticancer therapy
Hussain, S., Tulsyan, S., Dar, S. A., Sisodiya, S., Abiha, U., Kumar, R., Mishra, B. N., & Haque, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.023 · Cited by 54
A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
Fontana, A., Cursaro, I., Carullo, G., Gemma, S., Butini, S., & Campiani, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710014 · Cited by 50
“Given that epigenetic modifications can contribute to the onset and progression of malignancies, the potential contribution of HDACs has been largely explored in different cancer types, leading to the FDA approval of pan-HDACis as anticancer drugs [91].”
BackgroundMetabolic Regulation of Epigenetic Modifications and Cell Differentiation in Cancer
Saggese, P., Sellitto, A., Martinez, C. A., Giurato, G., Nassa, G., Rizzo, F. M., Tarallo, R., & Scafoglio, C. (2020) · Cancers · doi:10.3390/cancers12123788 · Cited by 51
“They can induce cell cycle arrest, apoptosis, autophagy in cancer cells, inhibit neoangiogenesis, and modulate immune responses [151].”
BackgroundCencioni, C., Trestini, I., Piro, G., Bria, E., Tortora, G., Carbone, C., & Spallotta, F. (2022) · Nutrients · doi:10.3390/nu14081542 · Cited by 54
Farhadipour, M., Arnauts, K., Clarysse, M., Thijs, T., Liszt, K. I., der Schueren, B. V., Ceulemans, L. J., Deleus, E., Lannoo, M., Ferrante, M., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108517 · Cited by 49
Santos, J., Hubert, T., & MILTHORPE, B. K. (2020) · Cells · doi:10.3390/cells9030619 · Cited by 49
“Valproic acid (VPA) is a short-chain fatty acid that is well known as a histone deacetylase (HDAC) inhibitor [10].”
BackgroundChianese, A., Santella, B., Ambrosino, A., Stelitano, D., Rinaldi, L., Galdiero, M., Zannella, C., & Franci, G. (2021) · Cancers · doi:10.3390/cancers13112761 · Cited by 50
“Currently, VV is under study and their activity can be enhanced by the use of HDACi [252,261].”
BackgroundExpression of H3K4me3 and H3K9ac in breast cancer
Berger, L., Kolben, T., Meister, S., Kolben, T. M., Schmoeckel, E., Mayr, D. C., Mahner, S., Jeschke, U., Ditsch, N. C., & Beyer, S. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03265-z · Cited by 54
Manogaran, P., Beeraka, N. M., Paulraj, R. S., Sathiyachandran, P., & Thammaiappa, M. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230111154537 · Cited by 47
Yang, Q., & Al-Hendy, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065778 · Cited by 48
Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors
Zheng, S., Guo, S., Zhong, Q., Zhang, C., Liu, J., Yang, L., Zhang, Q., & Wang, G. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00504 · Cited by 46
Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet
Martínez, V. G., Munera-Maravilla, E., Bernardini, A., Rubio, C., Suárez-Cabrera, C., Segovia, C., Lodewijk, I., Dueñas, M., Martínez‐Fernández, M., & Paramio, J. M. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01125 · Cited by 48
Ali, M. K., Shahin, S. M., Sabri, N. A., Al-Hendy, A. A., & Yang, Q. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz227 · Cited by 46
Jiang, W., Xia, T., Liu, C., Li, J., Zhang, W., & Sun, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.705903 · Cited by 55
Wang, Y., Sun, M., Wang, Y., Qin, J., Zhang, Y., Pang, Y., Yao, Y., Yang, H., & Duan, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113790 · Cited by 45
Wang, Y., & Tortorella, M. D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114039 · Cited by 47
Schäker‐Hübner, L., Haschemi, R., Büch, T., Kraft, F. B., Brumme, B., Schöler, A., Jenke, R., Meiler, J., Aigner, A. M., Bendas, G., et al. (2022) · ChemMedChem · doi:10.1002/cmdc.202100755 · Cited by 44
Small molecules as tools to study the chemical epigenetics of lysine acetylation
Schiedel, M., & Conway, S. J. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.06.015 · Cited by 42
Guenter, R. E., Aweda, T. A., Matos, D. M. C., Jang, S., Whitt, J. D., Cheng, Y., Liu, M., Chen, H., Lapi, S. E., & Jaskula‐Sztul, R. (2019) · Surgery · doi:10.1016/j.surg.2019.05.092 · Cited by 44
Histone deacetylase 3 controls lung alveolar macrophage development and homeostasis
Yao, Y., Liu, Q., Adrianto, I., Wu, X., Glassbrook, J. E., Khalasawi, N., Yin, C., Yi, Q., Dong, Z., Geissmann, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17630-6 · Cited by 53
Evidence for Modulation of Substance Use Disorders by the Gut Microbiome: Hidden in Plain Sight
Angoa‐Pérez, M., & Kuhn, D. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000144 · Cited by 45
“Broadly speaking, drugs of abuse can modulate gene transcription and expression via epigenetic mechanisms (Nestler, 2014;Cadet, 2016;Ajonijebu et al., 2017) such that chronic use leads to histone hypoacetylation via the action of HDACs.”
BackgroundInfluentialInoue, F., Sone, K., Toyohara, Y., Takahashi, Y., Kukita, A., Hara, A., Taguchi, A., Tanikawa, M., Tsuruga, T., & Osuga, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052305 · Cited by 47
“Combination therapy with TSA and paclitaxel enhances inhibition of cell growth in EC cell lines [103].”
BackgroundThe epigenetics of breast cancer – Opportunities for diagnostics, risk stratification and therapy
Schröder, R., Illert, A. L., Erbes, T., Flotho, C., Lübbert, M., & Duque‐Afonso, J. (2021) · Epigenetics · doi:10.1080/15592294.2021.1940644 · Cited by 52
Yang, H., Sun, B., Xu, K., He, Y., Zhang, T., Hall, S. R. R., Tan, S. T., Schmid, R. A., Peng, R., Hu, G., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103457 · Cited by 46
Dai, M., Liu, M., Yang, H., Küçük, C., & You, H. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00356-0 · Cited by 53
“This transcriptional modulation includes the re-expression of genes that were silenced during tumorigenesis in cancer cells, including tumor antigens, antigen-processing and presentation machinery genes, and tumor suppressor genes [81].”
BackgroundExposure time versus cytotoxicity for anticancer agents
Evans, D. M., Fang, J., Silvers, T. R., Delosh, R., Laudeman, J. A., Ogle, C., Reinhart, R. A., Selby, M., Bowles, L., Connelly, J., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03863-w · Cited by 52
Reva, K., Laranjinha, J. A. N., & Rocha, B. S. (2023) · Metabolites · doi:10.3390/metabo13030375 · Cited by 45
Ryu, Y., Kee, H. J., Sun, S., Seok, Y. M., Choi, S. Y., Kim, G. R., Kee, S., Pflieger, M., Kurz, T., Kim, H.-S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213186 · Cited by 47
Histone Deacetylase Inhibitors Dose-Dependently Switch Neutrophil Death from NETosis to Apoptosis
Hamam, H. J., & Palaniyar, N. (2019) · Biomolecules · doi:10.3390/biom9050184 · Cited by 46
van Tilburg, C. M., Milde, T., Witt, R., Ecker, J., Hielscher, T., Seitz, A., Schenk, J.-P., Buhl, J. L., Riehl, D., Frühwald, M. C., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0775-1 · Cited by 44
Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway
Idso, J. M., Lao, S., Schloemer, N. J., Knipstein, J. A., Burns, R., Thakar, M. S., & Malarkannan, S. (2020) · Oncotarget · doi:10.18632/oncotarget.27546 · Cited by 43
Livshits, G., & Kalinkovich, A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102267 · Cited by 47
Kawamura, Y., Takouda, J., Yoshimoto, K., & Nakashima, K. (2018) · Cell Biology and Toxicology · doi:10.1007/s10565-017-9420-y · Cited by 47
“Although anti-cancer mechanisms differ according to both the cancer type and HDACs, HDAC inhibitors seem to be promising anti-cancer drugs, particularly when used in combination with conventional multimodal therapy (Eckschlager et al. 2017).”
BackgroundMethodInfluentialLive-cell epigenome manipulation by synthetic histone acetylation catalyst system
Fujiwara, Y., Yamanashi, Y., Fujimura, A., Sato, Y., Kujirai, T., Kurumizaka, H., Kimurâ, H., Yamatsugu, K., Kawashima, S. A., & Kanai, M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019554118 · Cited by 45
HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer
Clements, M. E., Holtslander, L., Edwards, C. M., Todd, V. M., Dooyema, S. D. R., Bullock, K. K., Bergdorf, K. N., Zahnow, C. A., Connolly, R. M., & Johnson, R. W. (2021) · Oncogene · doi:10.1038/s41388-021-01931-1 · Cited by 45
“Several HDACi are US Food and Drug Administration-approved for hematological malignancies [8], and several including entinostat and vorinostat are currently being tested in ~70 clinical trials for early, advanced, and metastatic breast cancer [9] [clinicaltrials.”
BackgroundHistone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma
Palamaris, K., Moutafi, M. K., Gakiopoulou, H., & Theocharis, S. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073660 · Cited by 43
Vural, S., Palmisano, A., Reinhold, W. C., Pommier, Y. G., Teicher, B. A., & Krushkal, J. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01026-4 · Cited by 42
“Some GMDs, e.g., HDACs, may indirectly regulate gene expression by modifying a diverse set of protein targets including transcription factors [154].”
BackgroundAnticancer clinical efficiency and stochastic mechanisms of belinostat
Omari, N. E., Bakrim, S., Khalid, A., Albratty, M., Abdalla, A. N., Lee, L., Goh, K. W., Ming, L. C., & Bouyahya, A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115212 · Cited by 41
New generation drugs for treatment of multiple myeloma
Alanazi, F. G., Kwa, F. A. A., Burchall, G., & Jackson, D. E. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.11.008 · Cited by 43
Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy
Mrakovcic, M., & Fröhlich, L. F. (2019) · Cancers · doi:10.3390/cancers12010109 · Cited by 43
Krishna Murthy, P., Sivashanmugam, K., Kandasamy, M., Rajasekaran, S., & Ravikumar, V. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118883 · Cited by 56
Oxadiazole derivatives: Histone deacetylase inhibitors in anticancer therapy and drug discovery
Matore, B. W., Banjare, P., Guria, T., Roy, P. P., & Singh, J. (2022) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2022.100058 · Cited by 54
Pramanik, S. D., Halder, A. K., Mukherjee, U., Kumar, D., Dey, Y. N., & Mogana, R. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.948217 · Cited by 47
HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1/JAK1/FGL1 axis in lung adenocarcinoma
Xu, T., Fang, Y., Gu, Y., Duo, X., Hu, T., Tao, Y., Xu, Y.-Y., Shen, H., Ma, P., & Shu, Y. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010077 · Cited by 48
“8 To date, five pan-HDACis, such as vorinostat (SAHA), have been approved by the Food and Drug Administration (FDA) as anticancer drugs.”
Varga, K., Hollósi, A., Pászty, K., Hegedüs, L., Szakács, G., Tímár, J., Papp, B., Enyedi, Á., & Padányi, R. (2018) · BMC Cancer · doi:10.1186/s12885-018-4945-x · Cited by 42
Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells
Wobser, M., Weber, A., Glunz, A., Tauch, S., Seitz, K., Butelmann, T., Hesbacher, S., Goebeler, M., Bartz, R., Kohlhof, H., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0719-4 · Cited by 42
Histone deacetylases in virus‐associated cancers
Mirzaei, H., Ghorbani, S., Khanizadeh, S., Namdari, H., Faghihloo, E., & Akbari, A. (2019) · Reviews in Medical Virology · doi:10.1002/rmv.2085 · Cited by 44
“of retinoic acid and thyroid hormone receptors (SMRT), to establish structures with chromatin remodeling functions.(12) Accumulating evidence suggests that HDACs are frequently dysregulated in various diseases such as cancer, thereby modulating gene expression and, hence, influencing disease outcomes.”
BackgroundLobo, J., Guimarães‐Teixeira, C., Barros‐Silva, D., Miranda‐Gonçalves, V., Camilo, V., Guimarães, R., Cantante, M., Braga, I. C., Maurício, J., Oing, C., et al. (2020) · Cancers · doi:10.3390/cancers12102903 · Cited by 42
“Indeed, apoptosis induction and cell cycle arrest are among the most frequently reported pathways elicited by HDACis [42], and these data are also in line with the results of Nettersheim et al.”
BackgroundMethodResultEpigenomics and immunotherapeutic advances in pediatric brain tumors
Abedalthagafi, M., Mobark, N. A., Alrashed, M. M., & Alharbi, M. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00173-4 · Cited by 45
Tilekar, K. N., Hess, J. D., Upadhyay, N., Bianco, A. L., Schweipert, M., Laghezza, A., Loiodice, F., Meyer‐Almes, F., Aguilera, R. J., Lavecchia, A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00491 · Cited by 41
Sirtuins as pharmacological targets in neurodegenerative and neuropsychiatric disorders
Leite, J. A., Ghirotto, B., Targhetta, V. P., de Lima, J., & Câmara, N. O. S. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15570 · Cited by 45
“Several HDAC inhibitors, for example, vorinostat (suberoylanilide hydroxamic acid®) (Falkenberg & Johnstone, 2014) and belinostat (Beleodaq®, PXD-101 or PXD101) (Finn et al., 2016) have been approved mainly for use in malignancies (Eckschlager et al., 2017).”
BackgroundInfluentialGanai, S. A., Sheikh, F. A., & Baba, Z. A. (2020) · Phytotherapy Research · doi:10.1002/ptr.6869 · Cited by 39
Sanaei, M., & Kavoosi, F. (2021) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2021.22.s1.89 · Cited by 39
Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer
Matthews, B., Bowden, N. A., & Wong‐Brown, M. W. (2021) · Cancers · doi:10.3390/cancers13235993 · Cited by 44
“There is evidence that HDACis could potentially play a role in the treatment of ovarian cancer, but they would need to be further improved to increase their efficacy whilst having tolerable side effects.”
BackgroundInfluentialLv, Z., Ji, T., Liu, J., Sun, X. S., & Liang, H. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117185 · Cited by 40
Mechanisms of HDACs in cancer development
Zhang, Y., Wang, H., Zhan, Z., Gan, L., & Bai, O. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529239 · Cited by 71
Wang, S., Chen, Y., Chow, J., Chien, M., Yang, S., Wen, Y., Lee, W.-J., & Tseng, T. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22807 · Cited by 40
“ing and/or downregulating expressions of proapoptotic and antiapoptotic genes.(27,28)Mechanistic studies have implicated activation of extrinsic or intrinsic apoptotic pathways as a mechanism of action of different HDACIs.”
BackgroundEto, S., Saeki, K., Yoshitake, R., Yoshimoto, S., Shinada, M., Ikeda, N., Kamoto, S., Tanaka, Y., Kato, D., Maeda, S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218382 · Cited by 40
Histone deacetylases as targets in autoimmune and autoinflammatory diseases
Hamminger, P., Rîca, R., & Ellmeier, W. (2020) · Advances in immunology · doi:10.1016/bs.ai.2020.06.001 · Cited by 43
Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma
Nawar, N., Bukhari, S., Adile, A., Suk, Y., Manaswiyoungkul, P., Toutah, K., Olaoye, O. O., Raouf, Y. S., Sedighi, A., Garcha, H. K., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01585 · Cited by 38
Recent Progress in Histone Deacetylase (HDAC) 1 Inhibitors as Anticancer Agent
Patel, P., Wahan, S. K., Vishakha, S., Kurmi, B. D., Gupta, G. D., Rajak, H., & Asati, V. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220624090542 · Cited by 40
Thommen, B. T., Passecker, A., Buser, T., Hitz, E., Voss, T. S., & Brancucci, N. M. B. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.802341 · Cited by 37
Zagni, C., Citarella, A., Oussama, M., Rescifina, A., Maugeri, A., Navarra, M., Scala, A., Piperno, A., & Micale, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040945 · Cited by 37
“However, there are no selective HDACIs approved for clinical use in oncology, albeit some of them reached Phase I or early Phase II trials [6].”
BackgroundMettananda, S., Yasara, N., Fisher, C. A., Taylor, S., Gibbons, R. J., & Higgs, D. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-48204-2 · Cited by 38
Sharma, M., Molehin, D., Castro‐Piedras, I., Martinez, E. G., & Pruitt, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-52723-3 · Cited by 41
Yan, W., Wu, T. H. Y., Leung, S. S. Y., & To, K. K. W. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118211 · Cited by 40
Marampon, F., Leoni, F., Mancini, A., Pietrantoni, I., Codenotti, S., Letizia, F., Megiorni, F., Porro, G., Galbiati, E., Pozzi, P., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2800-8 · Cited by 38
Sundaramurthi, H., Roche, S. L., Grice, G. L., Moran, A. L., Dillion, E., Campiani, G., Nathan, J. A., & Kennedy, B. N. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00689 · Cited by 37
Goetting, I., Jendrossek, V., & Matschke, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228563 · Cited by 38
HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells
Ali, A., Zhang, F., Maguire, A., Byrne, T., Weiner‐Gorzel, K., Bridgett, S., O’Toole, S. A., O’Leary, J. J., Beggan, C., Fitzpatrick, P., et al. (2020) · Cancers · doi:10.3390/cancers12123734 · Cited by 42
“HDAC6 modulates the stress response, oncogenesis, cell motility, and many other cancer-related signaling networks in ovarian cancer cells [10,24], and its inhibition significantly improved the survival of mice bearing AT-Rich Interaction Domain 1A (ARID1A)-mutated ovarian tumors, correlating with suppressed tumor grow…”
BackgroundKlepinina, L., Klepinin, A., Truu, L., Chekulayev, V. A., Vija, H., Kuus, K., Teino, I., Pook, M., Maimets, T., & Käämbre, T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245348 · Cited by 37
“The anti-carcinogenic effect of butyrate has been attributed to its function as a histone deacetylase (HDAC) inhibitorIn various cancer cell lines, HDAC inhibitors suppress cell proliferation via cell cycle arrest, induce differentiation and apoptosis, reduce angiogenesis and modulate immune response [30].”
BackgroundCREB Inactivation by HDAC1/PP1γ Contributes to Dopaminergic Neurodegeneration in Parkinson's Disease
Xu, X., He, X., Zhang, Z., Chen, Y., Li, J., Ma, S., Huang, Q., & Li, M. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.1419-21.2022 · Cited by 39
HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma
Shen, C., Li, M., Duan, Y., Jiang, X., Hou, X., Xue, F., Zhang, Y., & Luo, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1170207 · Cited by 44
“p53 protein transcription and thus induce apoptosis of drugresistant cancer cells (30, 109, 111).”
BackgroundTan, Y., Zhang, S., Zhu, H., Chu, Y., Zhou, H., Liu, D., & Huo, J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2018.11.48 · Cited by 35
“At the present, four drugs, namely vorinostat (SAHA) (27), romidepsin (FK-228) (28), belinostat (PXD101) (29) and panobinostat (LBH-589) (30) have granted the United States Food and Drug Administration’s approval for cancer treatment and several HDACIs are currently in various phases of clinical trials, either as mono…”
BackgroundMoler, E. R. V., Abakir, A., Eleftheriou, M., Johnson, J. S., Krutovsky, K. V., Lewis, L. C., Ruzov, A. S., Whipple, A. V., & Rajora, O. P. (2018) · Population genomics · doi:10.1007/13836_2018_59 · Cited by 40
Calcagno, D. Q., Wisnieski, F., Mota, E. R. D. S., de Sousa, S. B. M., da Silva, J. M. C., Leal, M. F., Gigek, C. O., Santos, L. C., Rasmussen, L. T., de Assumpção, P. P., et al. (2019) · Epigenomics · doi:10.2217/epi-2018-0081 · Cited by 44
Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy
Wang, W., & Tse‐Dinh, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190401113350 · Cited by 36
Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas
Pei, Y., Wong, J. H.-Y., & Robertson, E. S. (2020) · Cancers · doi:10.3390/cancers12092565 · Cited by 37
Protein Acetylation/Deacetylation: A Potential Strategy for Fungal Infection Control
Chen, J.-Z., Liu, Q., Zeng, L., & Huang, X. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.574736 · Cited by 38
Broad-Spectrum HDAC Inhibitors Promote Autophagy through FOXO Transcription Factors in Neuroblastoma
Körholz, K. F., Ridinger, J., Krunic, D., Najafi, S., Gerloff, X. F., Frese, K., Meder, B., Peterziel, H., Vega-Rubín-de-Celis, S., Witt, O., et al. (2021) · Cells · doi:10.3390/cells10051001 · Cited by 36
“Despite all evidence that HDACis are promising anti-cancer targets, only a few broad-spectrum inhibitors have been approved for clinical use as of now, mostly because HDACi monotherapies displayed limited success in clinical trials [62].”
BackgroundAnti-tumor pharmacology of natural products targeting mitosis
Huang, M., Liu, C., Shao, Y., Zhou, S., Hu, G., Yin, S., Pu, W., & Yu, H. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0006 · Cited by 41
Targeting the Epigenome in Malignant Melanoma: Facts, Challenges and Therapeutic Promises
Anestopoulos, I., Kyriakou, S., Tragkola, V., Paraskevaidis, I., Tzika, E., Mitsiogianni, M., Deligiorgi, M. V., Petrakis, G., Trafalis, D. T., Botaitis, S., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108301 · Cited by 42
Bendridi, N., Selmi, A., Balcerczyk, A., & Pirola, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314564 · Cited by 40
“Cl ss I HDACs (HDAC1 nd 2) are zinc-dependent enzymes and class III HDACs (sirtuin : SIRT1, SIRT2) are NAD+-dependent enzymes, both i c l- ifi ti , fi , i t i ti , as erasers [31,32] (Figure 2).”
BackgroundChalcones and Gastrointestinal Cancers: Experimental Evidence
Michalková, R., Kello, M., Čižmáriková, M., Bardelčíková, A., Mirossay, L., & Mojžíš, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065964 · Cited by 38
“death, the suppression of neovascularization and the modulation of immune response [108].”
BackgroundRelevance of the natural HDAC inhibitor sulforaphane as a chemopreventive agent in urologic tumors
Juengel, E., Erb, H. H. H., Haferkamp, A., Rutz, J., Chun, F. K. ‐., & Blaheta, R. A. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.017 · Cited by 36
Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4
Diener, J., Baggiolini, A., Pernebrink, M., Dalcher, D., Lerra, L., Cheng, P. F., Varum, S., Häusel, J., Stierli, S., Treier, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25326-8 · Cited by 34
Histone Deacetylases 1 and 2 in Memory Function
Pao, P.-C., & Tsai, L.-H. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00775 · Cited by 34
Optimizing poly ( ADP ‐ribose) polymerase inhibition through combined epigenetic and immunotherapy
Prasanna, T., Wu, F., Khanna, K. K., Yip, D., Malik, L., Dahlstrom, J. E., & Rao, S. (2018) · Cancer Science · doi:10.1111/cas.13799 · Cited by 40
Steinemann, G., Dittmer, A., Schmidt, J., Josuttis, D., Fähling, M., Biersack, B., Beindorff, N., Koziolek, E. J., Schobert, R., Brenner, W., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12582 · Cited by 35
“Hence, the investigations point toward a potential of HDAC inhibition as a therapeutic option, but also show that the spectrum of effectiveness strongly depends on the specific mode of HDAC inhibition of the different classes of inhibitors (short-chain fatty acids, benzamides, cyclic tetrapeptides, sirtuin inhibitors,…”
Background
Metadata
- Authors
- Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J.
- Affiliations
- Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84/1, Prague 5 CZ-150 06, Czech Republic
- Charles University (CZ)
- Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030/8, Prague 2 CZ-128 43, Czech Republic
- ORCID
- Stiborova, Marie
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-07-01
- Volume
- 18
- Issue
- 7
- Pages
- 1414
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5535906
- OpenAlex
- W2724336500
- Cited by
- 1,206
- References
- 184
- Citations by year
- 2026: 64 · 2025: 107 · 2024: 107 · 2023: 140 · 2022: 164 · 2021: 195 · 2020: 170 · 2019: 164 · 2018: 85 · 2017: 9
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministerstvo Zdravotnictví Ceské Republiky (00064203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, epigenetic regulation, histone acetylation, histone acetyltransferase, differentiation therapy, angiogenesis, immune response, vorinostat, romidepsin, belinostat, panobinostat, T-cell lymphoma, multiple myeloma, epigenetic therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Signal Transduction, Gene Expression Regulation, Neoplastic, Apoptosis, Angiogenesis Inhibitors, Epigenesis, Genetic, Histone Deacetylase Inhibitors, Immunomodulation, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
